Slingshot members are tracking this event:

CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
  • Study stopped early after review of safety and efficacy data demonstrated clear proof-of-concept and opportunity for further dose reduction to optimize clinical safety and efficacy
  • Large statistically significant decreases seen for ALP in patients receiving MBX-8025; reversible dose related liver enzyme elevations observed
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 31, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Mbx-8025, Primary Biliary Cholangitis, Pbc, Pparδ Agonist